Articles

Indy-founded drug firm lands nearly $23M to fight rare disease

Two local men who have been working on a potential blockbuster treatment for a rare and debilitating disease are hopeful that a major injection of venture capital will provide the boost needed to move the drug to market—even if it means sweeping changes for their company.

Read More

At Eli Lilly, tears, heartbreak and renewed determination

Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.

Read More
rop-dna-research-010416-2col.jpg

Deal puts IU doctor’s research on path to market

A professor in the Indiana School of Medicine is hopeful that an antibiotic cocktail he invented will one day improve the lives of millions of people, thanks in part to the Indiana University Research and Technology Corp., formed in 1997 to make work done by IU faculty and researchers available for commercial development.

Read More

Potential Alzheimer’s drug further backs protein hypothesis

The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.

Read More

Senate panel considers ‘right-to-try’ trial drugs bill

An Indiana Senate committee is considering a bill that would give terminally ill patients easier access to experimental drugs that have not received full federal approval. Indiana is one of nearly two dozen states that are considering the legislation.

Read More

Lilly’s Cyramza gets new marketing approval

Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.

Read More

Alzheimer’s tests present dilemma of knowing the future

While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.

Read More